Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency and is marketed in the European Union as a prescription‑only product.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Fresenius acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

Acute attacks of hereditary angioedema (C1‑inhibitor deficiency): rapid reduction of swelling and pain. Hereditary angioedema type I and II: provides symptomatic relief during attacks. Bradykinin‑mediated angioedema: alleviates swelling caused by excess bradykinin.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Erythema: localized redness around the injection area. - Nausea: mild gastrointestinal upset. - Headache: transient head discomfort. - Dizziness: brief episodes of light‑headedness. - Swelling at injection site: minor local edema.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling in other regions. - Thrombocytopenia: low platelet count observed in rare cases. - Urticaria: widespread hives.

Before using Icatibant Fresenius, consider the following safety measures.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh maternal benefit against infant risk. Renal impairment: no dosage adjustment required, but monitor for accumulation. Concomitant ACE inhibitors: may increase bradykinin levels; observe for worsening edema. Hypersensitivity: discontinue immediately if allergic signs appear. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that affect the bradykinin system or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may precipitate angioedema. - Angiotensin receptor blockers: similar risk of enhanced bradykinin activity. - Other bradykinin B2 antagonists: no added benefit and may increase adverse events.

Moderate Interactions (Monitor Closely): - C1‑inhibitor concentrate: sequential use may be needed; monitor clinical response. - Antihistamines: may mask early signs of hypersensitivity; observe patient. - NSAIDs: can exacerbate swelling; watch for increased edema.